Table 1 Patient demographics. The clinical characteristics of 48 patients with mutational and/or gene expression data
Clinical characteristics | n (%) | |
|---|---|---|
Diagnosis | ||
Age (years) | Mean | 54 |
Range | 27–86 | |
Disease status | EBC | 41 (85) |
Locally advanced | 5 (10) | |
Metastatic | 2 (5) | |
Age at start of AI treatment (years) | Mean | 62 |
Range | 33–88 | |
Pre-AI biopsy | ||
Site | Primary | 30 (62) |
Local recurrence | 17 (35) | |
Distant recurrence | 1 (2) | |
Disease status | EBC | 24 (50) |
Locoregional recurrence | 20 (42) | |
MBC | 4 (8) | |
AI therapy b/w 1st and 2nd biopsy | ||
Type | Letrozole | 25 (52) |
Anastrozole | 21 (44) | |
Exemestane | 2 (5) | |
Disease setting for AI therapy | Adj/neoadj | 9 (19) |
Local recurrence | 25 (52) | |
Metastatic | 14 (30) | |
Post-AI biopsy | ||
Site | Primary | 7 (15) |
Local recurrence | 26 (54) | |
Distant recurrence | 15 (31) | |
Disease status | EBC | 3 (6) |
Locoregional recurrence | 17 (36) | |
MBC | 28 (58) | |
Endocrine therapy prior AI treatment | None | 11 (23) |
Tamoxifen | 31 (65) | |
Tamoxifen + AI | 5 (10) | |
Grosrelin | 1 (2) | |
Endocrine therapy after PD on AI | AI | 31 (65) |
Tamoxifen | 7 (15) | |
Fulvestrant | 5 (10) | |
HER2 status of either tissues | HER2 positivea | 7 (15) |
Trastuzumab received | 6 (13) | |
Overall survivalb (years) | Median | 8.75 |
Range | 2-33 | |
